Diffinity Genomics, a Rochester–based biotechnology company, has a new president. The company announced on Friday that Joseph Marasco would assume the role.
Diffinity CEO Jeffrey Helfer will step down from his position and from the company’s board of directors. Marasco has been appointed to the board to fill the vacancy.
Helfer will continue in a new product and business development role and as an executive adviser through the leadership transition.
(Sponsored)
How Do Value Conclusions and Value Calculations Differ?
The value of a business is relevant in a wide variety of legal contexts, including divorces, shareholder disputes, mergers, bankruptcy and tax planning. Nevertheless, not every so-called “valuation” service is
“Borderline” Overtime Exemptions Require Careful Analysis and Precautionary Measures
Q: We have an employee who we believe is properly classified as exempt from receiving overtime under the Fair Labor Standards Act (FLSA) but it is a “borderline” case. In
Since 2007, Marasco has been CEO of Chiral Quest Corp., a fine chemical and active pharmaceutical ingredient manufacturing firm. He has held leadership roles at early-stage and publicly traded firms including Dow Chemical, Beckman, and Kaneka, according to Diffinity.
The changes are part of Diffinity’s succession plan to help ensure it has access to the expertise necessary for its present growth stage, according to the company.
Diffinity has received investment from Central New York sources including the Syracuse–based Seed Capital Fund of CNY, LLC and the Allyn Family Capital Fund, LLC. The company develops products used in isolating and analyzing nucleic acids like DNA.
It’s work that life-sciences professionals perform on a regular basis. The company’s first two products are pipette tips used to move liquids in a laboratory setting.
The tips contain a proprietary material created using nanotechnology that allows for rapid purification of samples, according to Diffinity.
Contact Tampone at ktampone@cnybj.com
